[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Multi Drug Resistant Antibiotics Market, 2012 to 2023

December 2017 | 218 pages | ID: M5B2096EB0DEN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Multi-Drug Resistant Antibiotics Market

Market Outline: Multi-Drug Resistant Antibiotics Market
Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.

Market Dynamics: Multi-Drug Resistant Antibiotics Market

Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.

Market Scope: Multi Drug Resistant Antibiotics Market

Global multi drug resistant antibiotics market is segmented based on type of bacteria, disease and distribution channel

Based on type of bacteria, it is segmented into

Multi Drug Resistant Enterococci
Multi Drug Resistant Staphylococci
Gram Negatives
Others

Based on disease, it is segmented into

Drug Resistant Tuberculosis
Others

Based on distribution channel, it is segmented into

Hospital Pharmacies
Retail Pharmacies
Others

Market Summary: Multi Drug Resistant Antibiotics Market
Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.

Region Anaysis: Multi Drug Resistant Antibiotics Market
Geographically, multi drug resistant antibiotics market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America multi drug resistant market is expected to grow at significant rates owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.

Market Participants: Multi Drug Resistant Antibiotics Market
Some of the players in Multi-Drug Resistant Antibiotics Market are F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Servieces Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.

Notable Market Developments: Multi Drug Resistant Antibiotics Market
In August 2017, U.S. FDA approved The Medicines Company’s Vabomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria
In May 2014, U.S. FDA approved Durata Therapeutic’s (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections

Key Features of the Report

The report provides granular level information about The market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry
The report tracks recent innovations, key developments and startup’s details that are working in The industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY

2. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET INTRODUCTION

2.1. Global Multi Drug Resistant Antibiotics Market – Taxonomy
2.2. Global Multi Drug Resistant Antibiotics Market –Definitions
  2.2.1. Type of Bacteria
  2.2.2. Distribution Channel

3. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multi Drug Resistant Antibiotics Market Dynamics – Factors Impact Analysis
3.6. Global Multi Drug Resistant Antibiotics Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Multi Drug Resistant Antibiotics Market – Product Innovations

4. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET, BY TYPE OF BACTERIA, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Type of Bacteria Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  5.1.1. Multi Drug Resistant Enterococci
    5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.1.1.3. Market Opportunity Analysis
  5.1.2. Multi Drug Resistant Staphylococci
    5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.1.2.3. Market Opportunity Analysis
  5.1.3. Gram Negatives
    5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.1.3.3. Market Opportunity Analysis
  5.1.4. Others
    5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.1.4.3. Market Opportunity Analysis

6. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Drug Resistant Tuberculosis
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Others
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis

7. MARKET OPPORTUNITY ANALYSIS GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Others
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis

8. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease Type, End User, and Region, 2017 – 2023

9. NORTH AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Multi Drug Resistant Enterococci
    9.1.1.2. Multi Drug Resistant Staphylococci
    9.1.1.3. Gram Negatives
    9.1.1.4. Others
  9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Drug Resistant Tuberculosis
    9.1.2.2. Others
  9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Retail Pharmacies
    9.1.3.3. Others
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease, End User and Country, 2017 – 2023
  9.1.6. North America Multi Drug Resistant Antibiotics Market Dynamics – Trends

10. EUROPE MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Multi Drug Resistant Enterococci
    10.1.1.2. Multi Drug Resistant Staphylococci
    10.1.1.3. Gram Negatives
    10.1.1.4. Others
  10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Drug Resistant Tuberculosis
    10.1.2.2. Others
  10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Retail Pharmacies
    10.1.3.3. Others
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends

11. ASIA-PACIFIC MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Multi Drug Resistant Enterococci
    11.1.1.2. Multi Drug Resistant Staphylococci
    11.1.1.3. Gram Negatives
    11.1.1.4. Others
  11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Drug Resistant Tuberculosis
    11.1.2.2. Others
  11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Retail Pharmacies
    11.1.3.3. Others
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
  11.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends

12. LATIN AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Multi Drug Resistant Enterococci
    12.1.1.2. Multi Drug Resistant Staphylococci
    12.1.1.3. Gram Negatives
    12.1.1.4. Others
  12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Drug Resistant Tuberculosis
    12.1.2.2. Others
  12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Retail Pharmacies
    12.1.3.3. Others
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Multi Drug Resistant Antibiotics Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Multi Drug Resistant Enterococci
    13.1.1.2. Multi Drug Resistant Staphylococci
    13.1.1.3. Gram Negatives
    13.1.1.4. Others
  13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Drug Resistant Tuberculosis
    13.1.2.2. Others
  13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Retail Pharmacies
    13.1.3.3. Others
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Multi Drug Resistant Antibiotics Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Achaogen, Inc (U.S.)
  14.2.2. Actelion Pharmaceuticals (Switzerland)
  14.2.3. GlaxoSmithKline Plc (U.K.)
  14.2.4. F. Hoffmann La Roche (Switzerland)
  14.2.5. Eli Lilly and Company (U.S.)
  14.2.6. Sanofi S.A. (France)
  14.2.7. Johnson & Johnson Services Inc., (U.S.)
  14.2.8. Pfizer Inc., (U.S.)
  14.2.9. Otsuka pharmaceutical (Japan)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS


More Publications